Preface

Mitochondrial decline is one of the recognised hallmarks of ageing, but no intervention marketed to “restore mitochondrial function” currently has high-certainty evidence for hard clinical outcomes (mortality, morbidity, disability) in healthy or at-risk ageing adults. The strongest human data are for surrogate/functional endpoints (vascular endothelial function, muscle endurance, biomarker target engagement), and almost all use in a longevity setting is off-label or experimental. This summary is intended as adjunctive to conventional primary/secondary care, not a replacement for it.



1. Scope

Covered:

– The clinical concept of age-related mitochondrial dysfunction and its assessment in a longevity clinic.

– The most-studied targeted interventions: NAD⁺ precursors (NR, NMN), mitochondria-targeted antioxidants (MitoQ), urolithin A, coenzyme Q10, elamipretide, metformin, and lifestyle mitohormesis (exercise, caloric restriction/time-restricted eating, ketogenic strategies), and photobiomodulation.

– Evidence grading, patient selection, work-up, practical dosing, monitoring and safety.

Not covered:

– Genetically confirmed primary mitochondrial disease (e.g. MELAS, Barth syndrome, primary mitochondrial myopathy) — these are secondary-care/specialist metabolic conditions with distinct pathways. Elamipretide data are included only for context/extrapolation.

– Paediatrics, and disease-specific licensed indications (e.g. CoQ10 in statin myopathy).

– Unvalidated commercial “mitochondrial function” direct-to-consumer tests.

All recommendations assume adjunctive use alongside conventional care, with explicit informed consent where off-label.

—

2. Background and pathophysiology

Biological rationale (robust mechanistically):

– Mitochondrial dysfunction — reduced oxidative phosphorylation capacity, increased mitochondrial reactive oxygen species (mtROS), impaired mitophagy/biogenesis, and declining NAD⁺ — is a recognised hallmark of ageing and contributes to sarcopenia, insulin resistance, vascular dysfunction and neurodegeneration.[1][2]

– Key targetable mechanisms: (i) mtROS/oxidative damage (MitoQ, CoQ10, elamipretide); (ii) mitophagy/quality control (urolithin A, exercise, caloric restriction); (iii) NAD⁺/sirtuin signalling (NR, NMN); (iv) mitohormesis — mild mitochondrial stress activating AMPK–PGC-1α–NRF2 adaptive programmes (exercise, fasting, ketogenic diet, metformin); (v) cardiolipin stabilisation and cristae/supercomplex integrity (elamipretide).[2][3][4]

Most robust human mechanistic evidence:

– NAD⁺ precursors reliably raise circulating/tissue NAD⁺ metabolites (target engagement confirmed).[5][6]

– MitoQ lowers markers of mtROS-related oxidative stress (oxidised LDL) and improves endothelial function in older adults.[7][8]

– 670 nm transcranial photobiomodulation increased brain ATP-synthase flux (³¹P MT-MRS) in older adults — first-in-human mechanistic signal only.[9]

– Exercise increases skeletal muscle mitochondrial content/respiration in humans, including in type 2 diabetes.[2]

Preclinical only (mechanistic plausibility, not translatable to clinical benefit): urolithin A and MIC lifespan extension in C. elegans/rodents; NMN restoring mitochondrial markers and lifespan/healthspan in mice; harmol mitohormesis and ketogenic-diet lifespan extension in mice.[10][11][2][12][13][14] These should not be presented to patients as evidence of human anti-ageing benefit.

—

3. Evidence base and grading

Study landscape: predominantly small, short (weeks–4 months) RCTs and crossover trials with surrogate/functional endpoints; several systematic reviews; large observational cohorts for metformin; no completed RCT demonstrating that any of these interventions extends human lifespan or reduces age-related multimorbidity (TAME and VA-IMPACT ongoing/proposed).[15][16]

GRADE-style certainty by intervention and outcome:

Intervention	Outcome	Certainty (GRADE)	Evidence statement	Recommendation
MitoQ	Vascular endothelial function (FMD), arterial stiffness	Low–Moderate	Small crossover RCTs (n≈20–23) show improved brachial FMD, mainly in those with baseline FMD <6% [7], [8], [17]	Conditional (surrogate only)
MitoQ	Physical function/strength in older adults	Low	RCT (n=18) null overall; possible benefit in ≥70y subgroup (exploratory) [18]	Only in research
Urolithin A	Muscle endurance / mitochondrial gene & biomarker changes	Low–Moderate	RCTs (n≈250 pooled) improve endurance and lower inflammatory/acylcarnitine markers; primary endpoints (6MWT, max ATP) often null [19], [20]	Conditional for muscle endurance
Urolithin A	Physical function (6MWT, VO₂peak), body composition	Low	Inconsistent/null across trials [19], [20]	Only in research for these endpoints
NAD⁺ precursors (NR/NMN)	NAD⁺ target engagement	Moderate–High	Consistent across ≥28 RCTs [5], [6]	N/A (biomarker only)
NAD⁺ precursors	Metabolic/functional healthspan outcomes	Low	Heterogeneous, often null; NR 2000 mg/day did not improve insulin sensitivity [2][5], [6]	Only in research for clinical benefit
CoQ10	All-cause mortality/HF hospitalisation in heart failure	Moderate	Q-SYMBIO RCT + Cochrane: probable reduction in mortality (RR 0.58) and HF hospitalisation [21], [22]	Conditional — but this is a disease indication, not longevity
CoQ10	Hypertension/general anti-ageing	Very low–Low	Inconclusive for BP; no longevity outcome data [23]	Only in research for longevity
Elamipretide	Function in primary mitochondrial myopathy	Moderate	MMPOWER-3 phase 3 RCT negative on primary endpoints [24]	Recommend against outside licensed disease/trials
Metformin	Mortality/age-related disease in non-diabetics	Low (observational)	Association only; RCT (TAME) not yet reported [15], [16], [25]	Only in research for longevity
Exercise	Mitochondrial biogenesis + hard outcomes	High (for health outcomes broadly)	Robust across populations [2]	Strong

GRADE domain notes applying across the drug/supplement rows: risk of bias — many trials unblinded or industry-linked, unclear allocation (CoQ10 Cochrane rated all studies unclear/high RoB);[22] inconsistency — heterogeneous endpoints and dosing; indirectness — surrogate endpoints and disease populations extrapolated to healthy ageing; imprecision — small samples, wide CIs; publication bias — plausible given supplement industry involvement and small positive trials.

—

4. Patient selection and indications

Who may reasonably be considered (adjunctive, consented):

– Middle-aged/older adults with impaired vascular function (e.g. FMD <6%): the only group with a positive MitoQ signal.[17][7]

– Older adults with early sarcopenia/reduced muscle endurance or average-to-low physical performance (6MWT ≤550 m, low ATP synthesis): urolithin A candidate group.[26][20]

– Adults with cardiometabolic risk who are already candidates for lifestyle mitohormesis (exercise, TRE) — highest-value, lowest-risk.

Exclusion / specialist input required:

– Suspected primary mitochondrial disease → refer to metabolic/neurology; do not self-manage.

– Pregnancy/breastfeeding (no safety data for these supplements in this context).

– Significant renal/hepatic impairment (dose caution; metformin contraindicated per eGFR thresholds).

– Active malignancy or on treatment where antioxidant supplementation may theoretically interfere — specialist discussion.

Regulatory/ethical status:

– NAD⁺ precursors, urolithin A, CoQ10 are marketed as food supplements (not MHRA-licensed medicines); use for “anti-ageing” is unlicensed/off-label in intent.

– MitoQ is a supplement; longevity use is experimental.

– Metformin for non-diabetic longevity is off-label; ideally within trials/registries.

– Elamipretide (Forzinity) is FDA-approved only for Barth syndrome ≥30 kg; any longevity use is not appropriate outside research.[27]

– Default position for all pharmacological/supplement mitochondrial interventions in longevity practice: adjunctive care with explicit informed consent, or within research frameworks — not standard care.

—

5. Assessment and baseline work-up

History and examination:

– Cardiometabolic risk (QRISK3), medication review (statins, metformin), frailty screen in older adults (e.g. clinical frailty scale, gait speed, grip strength), exercise capacity and physical activity.

– Screen for red-flag features suggesting primary mitochondrial disease (ptosis, ophthalmoplegia, sensorineural deafness, exercise intolerance out of proportion, family history, unexplained multi-organ involvement) → refer rather than treat.

Baseline investigations (tailored, avoid low-yield testing):

– Bloods: FBC, U&E/eGFR, LFTs, HbA1c/fasting glucose, lipids, TSH, vitamin B12/folate, vitamin D; hs-CRP as an inflammation marker relevant to several interventions.[26]

– Functional tests: grip strength, gait speed/SPPB, 6-minute walk distance; VO₂peak if performance-oriented.

– Optional/experimental (flag as not validated for clinical decisions): plasma acylcarnitines, GDF15/FGF21 as mitochondrial stress mitokines, MRS-based muscle/brain ATP flux (research setting).[3]

Risk stratification:

– Low harm/high acceptability: exercise, dietary mitohormesis, CoQ10, urolithin A, NAD⁺ precursors at label doses.

– Higher scrutiny: metformin (GI tolerance, B12 depletion, renal thresholds), any parenteral NAD⁺ (no outcome evidence).[5]

Baseline documentation: functional metrics, biomarker panel, indication, off-label status and consent, and the specific pre-defined endpoint that will be used to decide continuation.

—

6. Dosing regimens and practical implementation

Regimens with the most human data (still surrogate-level):

– MitoQ (mitoquinone mesylate): 20 mg once daily orally; supported by chronic 6-week vascular RCT data. Higher acute doses (80–160 mg) used only in research.[7][17]

– Urolithin A: 500–1000 mg once daily orally; 1000 mg/day for ~4 months used in the endurance-positive trials; bioavailable, t½ ≈17–22 h.[26][20]

– CoQ10 (ubiquinone/ubiquinol): commonly 100–300 mg/day (Q-SYMBIO used 300 mg/day) — evidence base is in heart failure, not longevity.[21][22]

– NAD⁺ precursors: NR up to ~1000–2000 mg/day, or NMN 250–1000 mg/day — reliably raise NAD⁺ but without demonstrated clinical benefit; no established longevity dose.[5][6]

Regimens requiring caution / extrapolated from early or disease data:

– Metformin (off-label longevity): typical 500 mg titrated to 1500–2000 mg/day with food; supported only by observational data and mechanism, RCT pending.[15][16]

– Parenteral NAD⁺/IV NMN: not recommended — no eligible outcomes trials, safety/biomarker data only.[5]

– Elamipretide: not for longevity use.

Non-pharmacological (highest value):

– Aerobic + resistance exercise: the best-evidenced mitochondrial biogenesis stimulus; standard prescription (e.g. ≥150 min/week moderate aerobic + 2× resistance sessions).[2]

– Caloric restriction / time-restricted eating / periodic ketogenic strategies: mitohormetic; human mitochondrial data limited to small mechanistic studies (e.g. 12-week ketogenic diet + exercise altered muscle mitochondrial function) — frame as metabolic-health interventions, not proven longevity therapy.[14][28]

– Photobiomodulation (red/near-infrared, ~620–1100 nm; cytochrome c oxidase target): parameters are dose-dependent and not standardised; 670 nm has a single positive brain-ATP mechanistic study. Longevity use is experimental; no validated protocol for anti-ageing endpoints.[29][9][30]

—

7. Monitoring, safety and follow-up

Monitoring plan:

– Re-assess the pre-specified functional endpoint (e.g. endurance, FMD, grip strength) at 8–16 weeks; if no meaningful change, stop.

– Bloods relevant to the agent: renal function and vitamin B12 for metformin; LFTs if clinically indicated; HbA1c/lipids for metabolic interventions.

– Track inflammation (hs-CRP) and functional metrics longer term (6–12 months).

– Experimental biomarkers (NAD⁺ metabolites, acylcarnitines, mitokines) may be tracked for engagement but should not be used as proof of clinical benefit.

Timepoints: baseline → 8–16 weeks (efficacy/tolerability decision) → 6 months → annually.

Adverse effects:

– Supplements (MitoQ, urolithin A, CoQ10, NR/NMN): generally well tolerated in trials; mainly mild GI effects; no serious safety signal over weeks–months, but long-term safety is unknown. CoQ10 Cochrane flagged low-quality evidence with possible harm signal — interpret cautiously.[5][6][19][20][22]

– Metformin: GI intolerance (common), vitamin B12 deficiency with chronic use, rare lactic acidosis (renal/hepatic/hypoxic states).

– Photobiomodulation: self-limiting erythema most common; eye protection needed.[31]

Actions for abnormal findings: stop if no benefit at reassessment or if adverse effects occur; reduce dose for GI intolerance; refer if new red-flag features of organ dysfunction emerge.

Interactions/comorbidity:

– Antioxidant supplements (MitoQ, CoQ10) may blunt some exercise-training adaptations mechanistically (mtROS are part of the adaptive signal) — counsel athletic patients.[3]

– CoQ10 may reduce warfarin effect (structural vitamin K similarity) — monitor INR.

– Metformin: caution with contrast, other AMPK/mitochondrial agents, and in frailty (appetite/weight loss).

Special populations: avoid in pregnancy/breastfeeding (no data); dose-adjust or avoid metformin by eGFR; in frailty use lowest effective doses and prioritise exercise/nutrition; in very old adults evidence is weakest and individualise.

—

8. Contraindications and cautions

Absolute:

– Known/suspected primary mitochondrial disease managed outside specialist care (refer).

– Pregnancy and breastfeeding for these off-label interventions.

– Elamipretide outside its licensed indication/trials.[27]

– Metformin where standard contraindications apply (severe renal impairment, decompensated hepatic disease, unstable HF/hypoxia).

Relative / specialist advice:

– Active cancer or immunosuppression (antioxidant and metabolic interventions — theoretical concerns).

– Competitive athletes seeking training adaptation (antioxidant blunting).[3]

– Polypharmacy/frailty (interaction and tolerability burden).

Harm likely to outweigh benefit with current evidence:

– Parenteral/IV NAD⁺ for anti-ageing.[5]

– Any intervention marketed to the patient as lifespan-extending — no human outcome evidence supports this claim.

—

9. Practical management scenarios

Scenario A — Middle-aged adult with multiple cardiometabolic risk factors, impaired FMD:

– Offer lifestyle mitohormesis first (strong): structured aerobic + resistance exercise, dietary optimisation/TRE.[2]

– Consider MitoQ 20 mg/day as adjunct if endothelial dysfunction persists (conditional, surrogate benefit only).[7]

– Steps: baseline cardiometabolic + functional/vascular assessment → consent covering off-label/surrogate status → initiate exercise ± MitoQ → reassess FMD/risk factors at 12 weeks → stop MitoQ if no change; continue lifestyle indefinitely; escalate to conventional CVD risk management (statin/antihypertensive) per NICE.

Scenario B — Older, frail patient with multimorbidity:

– Prioritise exercise/resistance training and protein/nutrition (strong); this is the intervention with genuine outcome evidence.[2]

– Consider urolithin A 500–1000 mg/day for muscle endurance if performance is low-average (conditional); MitoQ possibly favours older/frailer subgroups but remains only in research.[26][20][18]

– Steps: frailty + renal/hepatic + medication review → minimise supplement/pill burden → consent → single time-limited trial with a defined functional endpoint (grip/gait/SPPB) → reassess at 12–16 weeks → discontinue if no functional gain; avoid stacking multiple unproven agents.

Scenario C — Patient already under specialist care (e.g. heart failure) wanting a mitochondrial adjunct:

– Do not alter guideline-directed therapy. For HFrEF specifically, CoQ10 has moderate-certainty evidence for reduced mortality/hospitalisation and may be considered as adjunct in discussion with cardiology (conditional). This is a disease indication, not longevity.[21][22]

– Steps: liaise with treating specialist → confirm no interaction (e.g. warfarin/INR) → consent → CoQ10 e.g. 300 mg/day → cardiology-led monitoring → stop if adverse effects or on specialist advice.

—

10. Research gaps and future directions

– No hard-outcome data: the central gap is absence of RCTs showing reduced mortality/multimorbidity or extended healthspan for any targeted mitochondrial intervention. TAME (metformin) and VA-IMPACT are pivotal and pending.[15][16]

– Surrogate-to-outcome linkage (NAD⁺ levels, FMD, endurance, ATP flux) is unproven for longevity endpoints — do not infer lifespan benefit from biomarkers.[5][9]

– Optimal population, dose and duration unknown for MitoQ (frail vs high-functioning), urolithin A, and NAD⁺ precursors.[18]

– Long-term safety of chronic supplementation and possible antioxidant–exercise interference need dedicated study.[3]

– Parenteral NAD⁺ should be restricted to trials given absent efficacy data.[5]

– Photobiomodulation requires standardised wavelength/fluence protocols and adequately powered functional trials before clinical adoption.[29][30]

Practically, in a UK longevity clinic the defensible position is: prioritise exercise and dietary mitohormesis; use targeted supplements only as time-limited, consented, endpoint-driven trials of one agent at a time; and route anything beyond this into registries or clinical trials.



Figure 3 MIC-induced mitophagy enhances mitochondrial health. Chamoli M, Rane A, Foulger A, et al. A Drug-Like Molecule Engages Nuclear Hormone Receptor DAF-12/FXR to Regulate Mitophagy and Extend Lifespan. Nature Aging. 2023;3(12):1529-1543. doi:10.1038/s43587-023-00524-9.

 

Figure 2 UA alters mitochondrial functions in C. elegans. Ryu D, Mouchiroud L, Andreux PA, et al. Urolithin a Induces Mitophagy and Prolongs Lifespan in C. Elegans and Increases Muscle Function in Rodents. Nature Medicine. 2016;22(8):879-88. doi:10.1038/nm.4132.

 

Figure 2 Effect of Urolithin A Supplementation on the 6-Minute Walk Distance and Maximal Adenosine Triphosphate (ATP) Production in Hand Muscles and Muscle Endurance Liu S, D’Amico D, Shankland E, et al. Effect of Urolithin a Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Network Open. 2022;5(1):e2144279. doi:10.1001/jamanetworkopen.2021.44279.

 

Figure 3 Effect of Urolithin A on Biomarkers of Mitochondrial Health and Inflammation Liu S, D’Amico D, Shankland E, et al. Effect of Urolithin a Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA Network Open. 2022;5(1):e2144279. doi:10.1001/jamanetworkopen.2021.44279.

 

Figure 3 Summary of treatment effect of elamipretide on efficacy endpoints. Karaa A, Haas R, Goldstein A, Vockley J, Cohen BH. A Randomized Crossover Trial of Elamipretide in Adults With Primary Mitochondrial Myopathy. Journal of Cachexia, Sarcopenia and Muscle. 2020;11(4):909-918. doi:10.1002/jcsm.12559.

 

Figure 2 Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) during the MMPOWER‐2 trial. Karaa A, Haas R, Goldstein A, Vockley J, Cohen BH. A Randomized Crossover Trial of Elamipretide in Adults With Primary Mitochondrial Myopathy. Journal of Cachexia, Sarcopenia and Muscle. 2020;11(4):909-918. doi:10.1002/jcsm.12559.

References

1. The Potential of Mitochondrial Therapeutics in the Treatment of Oxidative Stress and Inflammation in Aging. Sinha JK, Jorwal K, Singh KK, et al. Molecular Neurobiology. 2025;62(6):6748-6763. doi:10.1007/s12035-024-04474-0.
2. Mitochondrial and metabolic dysfunction in ageing and age-related diseases. Amorim JA, Coppotelli G, Rolo AP, et al. Nature Reviews. Endocrinology. 2022;18(4):243-258. doi:10.1038/s41574-021-00626-7.
3. What Are the Roles of Mitochondrial Stress Responses and Mitohormesis in Neurodegenerative Disorders?. Benarroch E. Neurology. 2026;106(3):e214618. doi:10.1212/WNL.0000000000214618.
4. Contemporary Insights Into Elamipretide’s Mitochondrial Mechanism of Action and Therapeutic Effects. Sabbah HN, Alder NN, Sparagna GC, et al. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2025;187:118056. doi:10.1016/j.biopha.2025.118056.
5. NAD⁺ Supplementation for Anti-Aging and Wellness: A PRISMA-guided Systematic Review of Preclinical and Clinical Evidence. Gallagher C, Emmanuel OO. Ageing Research Reviews. 2026;116:103057. doi:10.1016/j.arr.2026.103057.
6. Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions. Freeberg KA, Udovich CC, Martens CR, Seals DR, Craighead DH. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2023;78(12):2435-2448. doi:10.1093/gerona/glad106.
7. Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults. Rossman MJ, Santos-Parker JR, Steward CAC, et al. Hypertension (Dallas, Tex. : 1979). 2018;71(6):1056-1063. doi:10.1161/HYPERTENSIONAHA.117.10787.
8. Chronic Mitochondria Antioxidant Treatment in Older Adults Alters the Circulating Milieu to Improve Endothelial Cell Function and Mitochondrial Oxidative Stress. Murray KO, Ludwig KR, Darvish S, et al. American Journal of Physiology. Heart and Circulatory Physiology. 2023;325(1):H187-H194. doi:10.1152/ajpheart.00270.2023.
9. Use of P Magnetisation Transfer Magnetic Resonance Spectroscopy to Measure ATP Changes After 670 nm Transcranial Photobiomodulation in Older Adults. Fear EJ, Torkelsen FH, Zamboni E, et al. Aging Cell. 2023;22(11):e14005. doi:10.1111/acel.14005.
10. A drug-like molecule engages nuclear hormone receptor DAF-12/FXR to regulate mitophagy and extend lifespan. Chamoli M, Rane A, Foulger A, et al. Nature Aging. 2023;3(12):1529-1543. doi:10.1038/s43587-023-00524-9.
11. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Ryu D, Mouchiroud L, Andreux PA, et al. Nature Medicine. 2016;22(8):879-88. doi:10.1038/nm.4132.
12. NAD + metabolism as a target for metabolic health: have we found the silver bullet?. Connell NJ, Houtkooper RH, Schrauwen P. Diabetologia. 2019;62(6):888-899. doi:10.1007/s00125-019-4831-3.
13. Peripheral modulation of antidepressant targets MAO-B and GABAAR by harmol induces mitohormesis and delays aging in preclinical models. Costa-Machado LF, Garcia-Dominguez E, McIntyre RL, et al. Nature Communications. 2023;14(1):2779. doi:10.1038/s41467-023-38410-y.
14. When a calorie is not just a calorie: diet quality and timing as mediators of metabolism and healthy aging. Mihaylova MM, Chaix A, Delibegovic M, et al. Cell Metabolism. 2023;35(7):1114-1131. doi:10.1016/j.cmet.2023.06.008.
15. Impact of Geroscience on Therapeutic Strategies for Older Adults With Cardiovascular Disease: JACC Scientific Statement. Forman DE, Kuchel GA, Newman JC, et al. Journal of the American College of Cardiology. 2023;82(7):631-647. doi:10.1016/j.jacc.2023.05.038.
16. From discoveries in ageing research to therapeutics for healthy ageing. Campisi J, Kapahi P, Lithgow GJ, et al. Nature. 2019;571(7764):183-192. doi:10.1038/s41586-019-1365-2.
17. Acute Effects of MitoQ on Vascular Endothelial Function Are Influenced by Cardiorespiratory Fitness and Baseline FMD in Middle-Aged and Older Adults. Carlini NA, Harber MP, Fleenor BS. The Journal of Physiology. 2024;602(9):1923-1937. doi:10.1113/JP285636.
18. Translational Studies of Chronic Supplementation With a Mitochondria-Targeted Antioxidant to Improve Physical Function With Ageing. Murray KO, Gioscia-Ryan RA, Justice JN, et al. The Journal of Physiology. 2026;604(7):2898-2922. doi:10.1113/JP289428.
19. Targeting Aging With Urolithin a in Humans: A Systematic Review. Kuerec AH, Lim XK, Khoo AL, et al. Ageing Research Reviews. 2024;100:102406. doi:10.1016/j.arr.2024.102406.
20. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. Liu S, D’Amico D, Shankland E, et al. JAMA Network Open. 2022;5(1):e2144279. doi:10.1001/jamanetworkopen.2021.44279.
21. Complementary and Alternative Medicines in the Management of Heart Failure: A Scientific Statement From the American Heart Association. Chow SL, Bozkurt B, Baker WL, et al. Circulation. 2023;147(2):e4-e30. doi:10.1161/CIR.0000000000001110.
22. Coenzyme Q10 for Heart Failure. Al Saadi T, Assaf Y, Farwati M, et al. The Cochrane Database of Systematic Reviews. 2021;(2):CD008684. doi:10.1002/14651858.CD008684.pub3.
23. Coenzyme Q10 as Adjunctive Therapy for Cardiovascular Disease and Hypertension: A Systematic Review. Sue-Ling CB, Abel WM, Sue-Ling K. The Journal of Nutrition. 2022;152(7):1666-1674. doi:10.1093/jn/nxac079.
24. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Karaa A, Bertini E, Carelli V, et al. Neurology. 2023;101(3):e238-e252. doi:10.1212/WNL.0000000000207402.
25. Concept and Connotation of the Geroprotective and Anti-Aging Effects of Metformin: From AMPK Activation to SASP Suppression. Aedh AI, Al-Kuraishy HM, Shokr MM, Alruwaili M, El-Saber Batiha G. Molecular and Cellular Endocrinology. 2026;618:112802. doi:10.1016/j.mce.2026.112802.
26. Mitochondria as Nutritional Targets to Maintain Muscle Health and Physical Function During Ageing. Broome SC, Whitfield J, Karagounis LG, Hawley JA. Sports Medicine (Auckland, N.Z.). 2024;54(9):2291-2309. doi:10.1007/s40279-024-02072-7.
27. FDA Orange Book. FDA Orange Book.
28. A Ketogenic Diet Combined With Exercise Alters Mitochondrial Function in Human Skeletal Muscle While Improving Metabolic Health. Miller VJ, LaFountain RA, Barnhart E, et al. American Journal of Physiology. Endocrinology and Metabolism. 2020;319(6):E995-E1007. doi:10.1152/ajpendo.00305.2020.
29. Light Buckets and Laser Beams: Mechanisms and Applications of Photobiomodulation (PBM) Therapy. Frankowski DW, Ferrucci L, Arany PR, et al. GeroScience. 2025;47(3):2777-2789. doi:10.1007/s11357-025-01505-z.
30. Mechanisms of Action and Clinical Research Progress of Photobiomodulation. Shi G, Wei K, Wang R, et al. Journal of Photochemistry and Photobiology. B, Biology. 2026;282:113529. doi:10.1016/j.jphotobiol.2026.113529.
31. Photobiomodulation CME Part I: Overview and Mechanism of Action. Maghfour J, Ozog DM, Mineroff J, et al. Journal of the American Academy of Dermatology. 2024;91(5):793-802. doi:10.1016/j.jaad.2023.10.073.
32. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. Karaa A, Haas R, Goldstein A, Vockley J, Cohen BH. Journal of Cachexia, Sarcopenia and Muscle. 2020;11(4):909-918. doi:10.1002/jcsm.12559.